Neoadjuvant camrelizumab in combination with chemotherapy followed by sequential radical surgery for locally advanced esophageal squamous cell carcinoma: postoperative pathological remission characteristics and influencing factors.

AiRuiKa (camrelizumab) - Elevar Therapeutics

http://www.ncbi.nlm.nih.gov/pubmed/42222400

Feng Wang; Jiaxin Pei; Mengmeng Yang; Taiying Lu; Yikai Han; Yushu Deng; Ziyi Xiao

Jun 2, 2026